Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.35 |
| ▸ | JAK2 | O60674 | 4/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 2/20 | 0.31 |
| ▸ | CCND1 | P24385 | 2/20 | 0.31 |
| ▸ | CCND3 | P30281 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041400 | 0.94 | JAK3 (0.36) | JAK3JAK2BRD4JAK1BRD2 | |
| SCHEMBL15277140 | 0.91 | JAK3 (0.35) | JAK3SRCCDK4CCND1 | |
| SCHEMBL15280220 | 0.85 | JAK3 (0.37) | JAK3SRCCCNT1CDK4CCND1 | |
| SCHEMBL15035818 | 0.75 | JAK3 (0.37) | JAK3JAK1CDK4CCND1CCND3 | |
| SCHEMBL15035904 | 0.72 | JAK3 (0.36) | JAK3CDK4CCND1CCND3 | |
| SCHEMBL15034830 | 0.72 | WEE1 (0.35) | JAK3CCNT1CDK4CCND1CCND3 | |
| SCHEMBL15035929 | 0.71 | CDK4 (0.36) | JAK3JAK2BRD4JAK1BRD2 | |
| SCHEMBL15035045 | 0.71 | JAK3 (0.35) | JAK3JAK2JAK1CCNT1CDK4 | |
| SCHEMBL15036391 | 0.70 | TNK2 (0.34) | JAK3JAK2BRD4TNK2CCNT1 | |
| SCHEMBL15034944 | 0.69 | JAK3 (0.35) | JAK3JAK2JAK1CCNT1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | JAK3 1901/4885JAK2 720/4885BRD4 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.